When CLL meets COVID-19.

In this issue of , Mato et al report an international, multicenter analysis of 198 patients with chronic lymphocytic leukemia (CLL) and symptomatic COVID-19. In this analysis, COVID-19 appears to be more severe in CLL patients than in the general population and, although risk factors are the same as for the general COVID-19 population, the outcome of patients needing admission is poor, with a case fatality rate of 37%. The Mato et al paper is particularly compelling as reports of COVID-19 in specific diseases are needed, particularly in cancer where COVID-19 adds to the physical and emotional distress these patients already suffer. Also, clinicians need guidance on how to advise and manage these patients.